vs
Side-by-side financial comparison of IGC Pharma, Inc. (IGC) and PureTech Health plc (PRTC). Click either name above to swap in a different company.
IGC Pharma, Inc. is the larger business by last-quarter revenue ($191.0K vs $180.0K, roughly 1.1× PureTech Health plc). IGC Pharma, Inc. runs the higher net margin — -953.4% vs -22820.6%, a 21867.2% gap on every dollar of revenue.
IGC Pharma, Inc. is a clinical-stage biopharmaceutical firm focused on developing and commercializing innovative cannabinoid-derived therapeutics. Its core pipeline targets treatments for neurodegenerative conditions, pain and rare diseases, with primary operations in North America and ongoing global market expansion.
PureTech Health plcPRTCEarnings & Financial Report
PureTech Health is an American biotechnology company which develops medicines to combat serious diseases. It is listed on the London Stock Exchange.
IGC vs PRTC — Head-to-Head
Income Statement — Q3 FY2025 vs Q4 FY2023
| Metric | | |
|---|---|---|
| Revenue | $191.0K | $180.0K |
| Net Profit | $-1.8M | $-41.1M |
| Gross Margin | 51.8% | — |
| Operating Margin | -1517.8% | -38908.9% |
| Net Margin | -953.4% | -22820.6% |
| Revenue YoY | -53.6% | — |
| Net Profit YoY | -6.1% | — |
| EPS (diluted) | $-0.02 | $-0.15 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q3 25 | $191.0K | — | ||
| Q2 25 | $328.0K | — | ||
| Q4 24 | $257.0K | — | ||
| Q3 24 | $412.0K | — | ||
| Q2 24 | $272.0K | — | ||
| Q1 24 | $295.0K | — | ||
| Q4 23 | $204.0K | $180.0K | ||
| Q3 23 | $291.0K | — |
| Q3 25 | $-1.8M | — | ||
| Q2 25 | $-1.6M | — | ||
| Q4 24 | $-1.8M | — | ||
| Q3 24 | $-1.7M | — | ||
| Q2 24 | $-2.4M | — | ||
| Q1 24 | $-2.9M | — | ||
| Q4 23 | $-5.6M | $-41.1M | ||
| Q3 23 | $-2.5M | — |
| Q3 25 | 51.8% | — | ||
| Q2 25 | 47.0% | — | ||
| Q4 24 | 40.5% | — | ||
| Q3 24 | 48.1% | — | ||
| Q2 24 | 59.9% | — | ||
| Q1 24 | 58.0% | — | ||
| Q4 23 | 65.2% | — | ||
| Q3 23 | 59.8% | — |
| Q3 25 | -1517.8% | — | ||
| Q2 25 | -580.8% | — | ||
| Q4 24 | -730.7% | — | ||
| Q3 24 | -427.2% | — | ||
| Q2 24 | -880.9% | — | ||
| Q1 24 | -735.6% | — | ||
| Q4 23 | -1469.6% | -38908.9% | ||
| Q3 23 | -856.0% | — |
| Q3 25 | -953.4% | — | ||
| Q2 25 | -487.5% | — | ||
| Q4 24 | -711.7% | — | ||
| Q3 24 | -416.7% | — | ||
| Q2 24 | -874.3% | — | ||
| Q1 24 | -978.0% | — | ||
| Q4 23 | -2739.7% | -22820.6% | ||
| Q3 23 | -842.3% | — |
| Q3 25 | $-0.02 | — | ||
| Q2 25 | $-0.02 | — | ||
| Q4 24 | $-0.02 | — | ||
| Q3 24 | $-0.02 | — | ||
| Q2 24 | $-0.03 | — | ||
| Q1 24 | — | — | ||
| Q4 23 | $-0.09 | $-0.15 | ||
| Q3 23 | $-0.05 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $1.1M | $191.1M |
| Total DebtLower is stronger | — | $0 |
| Stockholders' EquityBook value | $8.1M | $458.2M |
| Total Assets | $9.7M | $694.0M |
| Debt / EquityLower = less leverage | — | 0.00× |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | $1.1M | — | ||
| Q2 25 | $454.0K | — | ||
| Q4 24 | $470.0K | — | ||
| Q3 24 | $1.5M | — | ||
| Q2 24 | $1.8M | — | ||
| Q1 24 | $1.2M | — | ||
| Q4 23 | $1.4M | $191.1M | ||
| Q3 23 | $3.1M | — |
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q4 23 | — | $0 | ||
| Q3 23 | — | — |
| Q3 25 | $8.1M | — | ||
| Q2 25 | $6.1M | — | ||
| Q4 24 | $6.3M | — | ||
| Q3 24 | $7.4M | — | ||
| Q2 24 | $7.9M | — | ||
| Q1 24 | — | — | ||
| Q4 23 | $9.1M | $458.2M | ||
| Q3 23 | $14.1M | — |
| Q3 25 | $9.7M | — | ||
| Q2 25 | $7.9M | — | ||
| Q4 24 | $9.1M | — | ||
| Q3 24 | $10.4M | — | ||
| Q2 24 | $10.6M | — | ||
| Q1 24 | $9.9M | — | ||
| Q4 23 | $11.3M | $694.0M | ||
| Q3 23 | $16.5M | — |
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q4 23 | — | 0.00× | ||
| Q3 23 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-2.1M | $-40.8M |
| Free Cash FlowOCF − Capex | $-2.1M | — |
| FCF MarginFCF / Revenue | -1109.4% | — |
| Capex IntensityCapex / Revenue | 15.2% | 0.0% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | $-2.1M | — | ||
| Q2 25 | $-1.4M | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $-996.0K | — | ||
| Q2 24 | $-1.8M | — | ||
| Q1 24 | $-526.0K | — | ||
| Q4 23 | $-1.6M | $-40.8M | ||
| Q3 23 | $-1.6M | — |
| Q3 25 | $-2.1M | — | ||
| Q2 25 | $-1.4M | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $-1.0M | — | ||
| Q2 24 | $-1.8M | — | ||
| Q1 24 | $-541.0K | — | ||
| Q4 23 | $-1.7M | — | ||
| Q3 23 | $-1.7M | — |
| Q3 25 | -1109.4% | — | ||
| Q2 25 | -431.4% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | -248.8% | — | ||
| Q2 24 | -658.1% | — | ||
| Q1 24 | -183.4% | — | ||
| Q4 23 | -811.3% | — | ||
| Q3 23 | -568.0% | — |
| Q3 25 | 15.2% | — | ||
| Q2 25 | 2.4% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 7.0% | — | ||
| Q2 24 | 14.0% | — | ||
| Q1 24 | 5.1% | — | ||
| Q4 23 | 33.3% | 0.0% | ||
| Q3 23 | 12.0% | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
